Aimovig: New migraine prevention drug approved by FDA

If you suffer from chronic migraines, relief is here.

According to The Associated Press, the Food and Drug Administration last week approved Aimovig, a monthly shot that aims to reduce migraines. The drug, developed by Amgen Inc. and Novartis AG, is "injected monthly just under the skin using a pen-like device," the AP reported. Its price tag: $6,900 annually before insurance.

>> On ActionNewsJax.com: New drug could reduce migraines

But how does Aimovig work? The FDA said it blocks "the activity of calcitonin gene-related peptide, a molecule that is involved in migraine attacks." Amgen researchers said participants in one study saw their migraines reduced by half and experienced "minor side effects" like colds, the AP reported.

>> Read more trending news

If Aimovig doesn't sound right for you, you're still in luck: Three similar shots and various pills to combat migraines are in the works.

– The Associated Press contributed to this report.

About the Author